{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2010"],"condition":["Prostatic Neoplasms","Neoplasm Metastasis","Melanoma","Colorectal Neoplasms","Neoplasms","Head and Neck Neoplasms"],"disease":["Prostatic Neoplasms","Neoplasm Metastasis","Melanoma","Colorectal Neoplasms","Head And Neck Neoplasms","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2093934"],"location":["United States"],"study_start_month":["12"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer","description":"The study will be conducted as an open label, single-dose, explorative study with patients with histologically proven cancer and, preferably, tumor positive lesions in previously performed nuclear medicine imaging examinations.\nThe investigational drug will be given as a single administration in a dose of </= 0.1 mg BAY94-9392 (300 MBq, +/- 10%). The total duration of the study for each patient will be approximately 8 days.","dates":{"creation":"2010-12-15"},"accession":"2093934","cross_references":{"ClinicalTrials___gov":["NCT01186601"]}}